ReviewFrontiers in cell and developmental biology2025
Periostin-integrin signaling in hepatocellular carcinoma: from biological function to clinical application.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Mechanism of POSTN Mediating M2 Polarization of Kupffer Cells to Promote Hepatic Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Characterization of cancer-associated fibroblast populations that promote tertiary lymphoid structure formation in murine melanoma tumors.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide and the most common primary tumor. Periostin (POSTN) is located in the extracellular matrix (ECM) and triggers tumor growth signals by binding to integrin receptors. The interaction of highly expressed POSTN with cell surface receptor integrins regulates intracellular signaling pathways and promotes HCC progression. In this review, the structure and isoforms of POSTN will be summarized, and the relationship between POSTN-integrin signaling and the diagnosis and prognosis of HCC patients, tumor cell proliferation and metastasis, immune escape, cancer stem cells and angiogenesis will be reviewed. The interaction between POSTN-integrin and the key signaling pathways of HCC and its mechanism in disease progression were emphasized, and the potential value of this signaling axis as a therapeutic target for HCC was explored, providing a theoretical basis for in-depth understanding of the pathophysiological process of HCC and the development of new therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.